RCS - Theracryf PLC - Publication of peer-reviewed data on SFX-01

TheracryfAnnouncement

10/07/2024 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240710:nRSJ9045Va&default-theme=true

RNS Number : 9045V  Theracryf PLC  10 July 2024

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Publication of peer reviewed data on the radiosensitising effects of SFX-01 in
Rhabdomyosarcoma

Alderley Park, UK - 10 July 2024: TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on oncology and neuropsychiatry, has been
informed that its collaborators at Sapienza University of Rome, have had their
work investigating the radiosensitising effects of SFX-01 in Rhabdomyosarcoma
(RMS) the most frequent soft tissue sarcoma in childhood, accepted for
publication in the peer reviewed journal, BMC Cancer.

A radiosensitising agent is a drug that makes tumour cells more sensitive to
radiation therapy, enhancing its effectiveness.

The work was carried out by Prof. Francesco Marampon of the Department of
Radiotherapy and Dr Simona Camero of Prof. Francesca Megiorni's research group
at the Department of Experimental Medicine at the Sapienza University of Rome.

The publication brings together positive data sets shared earlier this year
where SFX-01 was shown to be effective, in-vitro as well as in-vivo, in
reducing the growth of tumour cells grown in a laboratory setting and tumour
masses in a mouse model of RMS. Both studies highlighted the potential for
additional and in some cases synergistic (a more positive outcome than would
be expected by simply adding the two agents together) effects of SFX-01 when
used alongside radiotherapy which is the current standard of care treatment
for patients.

Dr Helen Kuhlman, TheraCryf's CBO, commented:

"The collaboration with Prof. Marampon's group has generated great insight
into the potential of SFX-01 as a radiosensitising agent and the mechanisms by
which it may be exerting its anti-tumour effects. I'd like to take this
opportunity to commend the work of the Sapienza group for the quality of the
data produced and the stimulating discourse around SFX-01 and its potential
for development as a therapeutic option for these patients who currently have
few alternatives."

Prof. Francesco Marampon, of Università Sapienza di Roma, Lead Investigator,
added:

"We are delighted that our data has been accepted by the esteemed publication,
BMC Cancer. RMS has been treated in the same way for many years, and research
suggests that the disease requires the increased local sensitisation of the
tumours to improve treatment options, therefore, the results from our in-vitro
and in-vivo data is very exciting. We are looking forward to taking the
research further forward with TheraCryf."

Rhabdomyosarcoma (RMS) is a rare type of cancer that forms in soft tissue and
can develop in muscle, fat, blood vessels, or in any of the other tissues that
support, surround and protect the organs of the body. RMS can occur at any
age, but most often affects children. The prognosis and treatment options
depend on the type of rhabdomyosarcoma, where it starts, tumour size and
whether the cancer has spread. Treatment is usually with a combination of
surgery, chemotherapy and radiation therapy. Currently, the long-term outcomes
in patients with metastatic rhabdomyosarcoma remain poor.

 

SFX-01 is a patented composition of synthetic sulforaphane and
alpha-cyclodextrin. TheraCryf has already completed three trials of SFX-01 in
patients, demonstrating good safety data, including a positive open label
trial in metastatic breast cancer
(https://www.sciencedirect.com/science/article/pii/S0923753419585635) using
the prototype capsule formulation.

TheraCryf's core technology is Sulforadex®, a method for synthesising and
stabilising sulforaphane and novel proprietary analogues based on
sulforaphane. Sulforaphanes have shown potential benefits in
neurodevelopmental disorders, oncology and inflammatory conditions. SFX-01,
TheraCryf's lead asset, is the only stabilised sulforaphane suitable for
clinical research and eventual approval as a medicine.

-Ends-

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Huw Jones, CEO
enquiries@theracryf.com

Toni Hänninen, CFO

Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD and Broker)                +44 (0)20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Vigo Consulting                                             +44 (0)20 7390 0230
 Rozi Morris
theracryf@vigoconsulting.com

 

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy* [*orphan indications].

Its strategy is to generate compelling data sets to preclinical and/or
clinical proof of concept and partner its clinical programmes with mid-size to
large pharma for larger trials and commercialisation. As well as a number of
industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and University of Connecticut.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C:/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABDGDRGSBDGSG